RxDoctor Payments Data

Yumi Jono

Gerontology · Olney, MDNPI 1437706561

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $609 and has fallen 69.4% since, to $186 in 2025.

$1,384in general payments, 2019–2025

Across 35 payments — averaging $39.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$314
  • Lundbeck LLC$164
  • Harmony Biosciences LLC$150
  • AbbVie$137
  • Insightec,inc$110
  • Biohaven Pharmaceutical Holding Company Ltd.$103
  • plus $406 from 11 others

What the payments were for

  • Food & beverage$1,384100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,384 in reported general payments places this provider in the 80th percentile of 108 gerontology providers in Maryland.

See all gerontology providers in Maryland

Medicare billing

Part B allowed, 2024
$36,943
Medicare patients
153
Services billed
900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate14$91,815
Lacosamide29$17,815
Aimovig AutoinjectorErenumab-Aooe15$11,333
Carbidopa-LevodopaCarbidopa/Levodopa112$3,919
Carbamazepine ErCarbamazepine11$3,121
Gabapentin118$2,707
Dimethyl Fumarate15$2,683
Levetiracetam50$1,865
Pramipexole DihydrochloridePramipexole Di-Hcl42$1,578
Pregabalin20$1,520
Sumatriptan Succinate55$1,437
Quetiapine Fumarate42$1,408
Carbamazepine22$1,395
Memantine Hcl36$1,326
Amitriptyline Hcl27$1,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$314$91,81514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 108 gerontology providers in Maryland.

Other gerontology in Olney

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →